The Chosun Ilbo on MSN

FDA Speeds Up Custom Gene Therapy Approvals With Existing Data

Last May, people were thrilled to learn that a 7-month-old baby who became the first in the world to receive a personalized ...
BioPharma Dive

Intellia pauses two CRISPR drug studies after safety scare

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...
Fierce Biotech

Intellia pauses phase 3 CRISPR trials after patient is hospitalized

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

FDA Clears Way for Faster Personalized Gene Editing Therapy

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
Hosted on MSN

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has gained 7% over this period. Now the key question is: Where could the stock be headed in the near term?

A Look at CRISPR Therapeutics’s Valuation Following New CTX460 Gene Editing Breakthrough Data

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...